Sign in
CABA Stock Price, Chart, Stats & News
Cabaletta Bio, Inc.
Save
Cabaletta Bio, Inc. (CABA) does not currently pay a dividend.
313.07M
Market cap
–
Current P/E
–
Forward P/E
CABA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -101.68% |
ROE | -121.73% |
D/E | 0.24x |
Interest coverage ratio | -85.95x |
CABA valuation
P/E | – |
P/S | – |
P/B | 2.45x |
P/CF | -2.09x |
P/FCF | -1.95x |
P/OCF | -2.09x |
PEG | -0.17x |
EV multiple | -1.82x |
About
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells.
Similar securities
Based on sector and market capitalization
Report issue